HERON THERAPEUTICS, INC. /DE/

A commercial-stage biotechnology company headquartered in Cary, North Carolina, Heron Therapeutics develops and commercializes therapeutics focused on oncology and perioperative care. The company's pipeline centers on its proprietary Biochronomer drug delivery technology, which enables extended-release administration of short-acting pharmaceutical agents over periods ranging from days to weeks through single-dose applications.

The company's marketed products include SUSTOL, an extended-release granisetron injection for chemotherapy-induced nausea and vomiting prevention, and CINVANTI, an intravenous aprepitant formulation for use in highly emetogenic and moderately emetogenic chemotherapy settings. In development are ZYNRELEF, a dual-acting local anesthetic combining bupivacaine and meloxicam for postoperative pain management, and APONVIE, an intravenous neurokinin-1 receptor antagonist for postoperative nausea and vomiting prevention in adults.

Heron operates with approximately 122 full-time employees and maintains operations in the United States. The company was originally founded in 1983 as A.P. Pharma, Inc., adopting its current name in January 2014. It is incorporated in Delaware and trades on the Nasdaq exchange.